Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: mixture (40), mix (142), blend (16), combination (297)

Ferinject - patient information

Description: Ferinject is special type of iron preparation given through a drip into a vein (also known as an 'infusion'). Ferinject is
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Ferinject.pdf

Stress-dose steroid treatment following zoledronic acid infusion - patient information

Description: This factsheet has been written to provide you with important information following your child's treatment with zoledronic acid.
Url: /Media/UHS-website-2019/Patientinformation/Childhealth/Stress-dose-steroid-treatment-following-zoledronic-acid-infusion-3003-PIL.pdf

DVd_Twice weekly_Daratumumab-Bortezomib-Dexamethasone_Cycles 1 to 8

Description: Chemotherapy Protocol Myeloma DVd (twice weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Twice-weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

Daratumumab

Description: Chemotherapy Protocol Myeloma Daratumumab Regimen • Myeloma – Daratumumab monotherapy Indication • Daratumumab monotherapy is recommen
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab.pdf

Blinatumomab

Description: Chemotherapy Protocol Acute lymphoblastic leukaemia (ALL) Blinatumomab (3, 4 day) Regimen • ALL – Blinatumomab (3, 4 day schedule) Indication • Treatment of Phi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Blinatumomab.pdf

ObinutuzumabVenetoclax LowRisk

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Obinutuzumab-Venetoclax (Low Risk) Regimen • CLL – Obinutuzumab-Venetoclax (Low Risk) Indica
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/ObinutuzumabVenetoclax-LowRisk.pdf

Chlorambucil_2_Obinutuzumab

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Chlorambucil (2 day)-Obinutuzumab (6 cycles) Regimen • CLL – Chlorambucil (2 day)-Obinutuzum
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-2-Obinutuzumab.pdf

Chlorambucil_14_Obinutuzumab

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Chlorambucil (14 day)-Obinutuzumab (6 cycles) Regimen • CLL – Chlorambucil (14 day)-Obinutuz
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-14-Obinutuzumab.pdf

Southampton PTC - Approved chemotherapy regimens 9 June 2020

Description: Appendix B: SOUTHAMPTON PAEDIATRIC ONCOLOGY PRINCIPAL TREATMENT CENTRE List of Approved Chemotherapy Regimens Updated 9th June 2020 Review Date
Url: /Media/UHS-website-2019/Docs/PaediatricOncology/Southampton-PTC-Approved-chemotherapy-regimens-9-June-2020.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone Cycles 1 to 8

Description: Chemotherapy Protocol Myeloma DVd (Weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (weekly
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

1 to 10 of 466

Previous 1 2 3 4 5 … Next